Loading clinical trials...

Buspirone as a Candidate Medication for Methamphetamine Abuse | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01843205•University of Kentucky

Summary

Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Lifetime methamphetamine use

Exclusion Criteria

•Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
•Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
•History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
•Females not currently using effective birth control
•Contraindications to methamphetamine or buspirone

Locations (1)

University of Kentucky Medical Center

Lexington, Kentucky, United States

Key Dates

Start Date

April 1, 2013

Primary Completion Date

March 1, 2017

Completion Date

March 1, 2017

Last Updated

February 7, 2018

Enrollment

ACTUAL participants

Conditions

Methamphetamine DependenceMethamphetamine Abuse

Interventions

Methamphetamine

DRUG

Placebo

DRUG

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799

Methamphetamine-dependenceMethamphetamine Abuse

View study

COMPLETEDNA

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

NCT04706624

Methamphetamine AbuseOpioid-use Disorder+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 7, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Buspirone as a Candidate Medication for Methamphetamine Abuse

Inclusion Criteria

Exclusion Criteria

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

tACS Treatment for Cognitive Impairments in Methamphetamine Addicts

rTMS for Stimulant Use Disorders

Risk and Protective Factors for Rural Methamphetamine Dependence

Demonstration of a Digital Care Program for Methamphetamine Use Disorder